From: "Bonate, Peter" Peter.Bonate@genzyme.com
Subject: [NMusers] Neutrophil transit models
Date: Thu, May 19, 2005 4:50 pm
Is anyone aware of any instances where the neutrophil transit models
developed by Friberg and Karlsson for cytotoxic agents have been used
to actually develop alternative dosing regimens for those drugs and
if so, what are the status of those trials?
Thanks,
Pete Bonate
Peter L. Bonate, PhD, FCP
Director, Pharmacokinetics
Genzyme Oncology
4545 Horizon Hill Blvd
San Antonio, TX 78229
phone: 210-949-8662
fax: 210-949-8219
email: peter.bonate@genzyme.com
_______________________________________________________